共 16 条
- [1] Pickering T.G., Ambulatory monitoring and blood pressure variability, (1991)
- [2] Pool J.L., Taylor A.A., Nelson E.B., Review of the effects of doxazosin, a new selective alpha1-adrenergic inhibitor, on lipoproteins in patients with essential hypertension, Am J Med, 87, pp. 53S-56S, (1989)
- [3] Rosenthal J.R., Clinical experience with doxazosin in general practice, Am Heart J, 116, pp. 1748-1757, (1988)
- [4] Hay Duck K., Schmeider H.T., Antihypertensive effects of doxazosin in systemic hypertension and comparison with terazosin, Am J Cardiol, 59, pp. 95G-98G, (1987)
- [5] Levy D., Walmsley P., Levenstein M., Principal results of the Hypertension and Lipid Trial (HALT), Am J Hypertens, 698, (1993)
- [6] Pickering T.G., Levenstein M., Walmsley P., Nighttime dosing of doxazosin has peak effect on morning ambulatory blood pressure. Results of the HALT study, Am J Hypertens, 7, pp. 844-847, (1994)
- [7] Pickering T.G., James G.D., Boddie C., Et al., How common is white coat hypertension?, JAMA, 259, pp. 225-228, (1988)
- [8] Gould B.A., Mann S., Davies A.B., Et al., Does placebo lower blood-pressure?, Lancet, 2, pp. 1377-1381, (1981)
- [9] Dupont A.G., Van Der Niepen P., Six R.O., Placebo does not lower ambulatory blood pressure, Br J Clin Pharmacol, 24, pp. 106-109, (1987)
- [10] Parati G., Pomidossi G., Casadei R., Et al., Evaluation of the antihypertensive effect of celiprolol by ambulatory blood pressure monitoring, Am J Cardiol, 61, pp. 27c-33c, (1988)